N4 Pharma (LON:N4P)‘s stock had its “speculative buy” rating reaffirmed by stock analysts at Beaufort Securities in a research note issued to investors on Thursday. They currently have a GBX 12 ($0.16) price objective on the stock. Beaufort Securities’ price objective suggests a potential upside of 47.69% from the stock’s previous close.

Shares of N4 Pharma (N4P) traded down GBX 0.38 ($0.01) on Thursday, reaching GBX 8.13 ($0.11). The company’s stock had a trading volume of 178,229 shares, compared to its average volume of 472,089. N4 Pharma has a 12 month low of GBX 4.88 ($0.07) and a 12 month high of GBX 12.50 ($0.17).

In other news, insider Nigel Theobald purchased 56,656 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of GBX 8 ($0.11) per share, with a total value of £4,532.48 ($6,070.01).

ILLEGAL ACTIVITY NOTICE: “Beaufort Securities Reiterates “Speculative Buy” Rating for N4 Pharma (N4P)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/30/beaufort-securities-reiterates-speculative-buy-rating-for-n4-pharma-n4p.html.

About N4 Pharma

N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.

Receive News & Ratings for N4 Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.